Therapeutic Plasma Exchange in Thailand: A 10-Year Retrospective Analysis

dc.contributor.authorVareesangthip K.
dc.contributor.authorOunhasuttiyanon A.
dc.contributor.authorPongsakornkullachart K.
dc.contributor.authorRochaikun K.
dc.contributor.authorJitprapaikulsan J.
dc.contributor.authorSiritho S.
dc.contributor.authorPermpikul P.
dc.contributor.authorLumpaopong A.
dc.contributor.authorVareesangthip K.
dc.contributor.correspondenceVareesangthip K.
dc.contributor.otherMahidol University
dc.date.accessioned2026-04-29T18:25:53Z
dc.date.available2026-04-29T18:25:53Z
dc.date.issued2026-01-01
dc.description.abstractBackground: Therapeutic plasma exchange (TPE) is a cornerstone of therapeutic apheresis across multiple subspecialties. While international registries have described global practice, nationwide data from Thailand are lacking. Methods: We conducted a 10-year retrospective analysis of all TPE admissions reimbursed under Thailand's Universal Health Coverage scheme (2014–2023). Cases were identified using ICD-9 code 997.1. Demographics, clinical indications, complications, outcomes, and costs were extracted from discharge records. Indications were categorized according to the 2023 American Society for Apheresis (ASFA) guidelines. Results: A total of 5884 admissions were identified. The mean age was 46.4 ± 20.6 years, 58.0% were male, and 13.0% were pediatric. TPE Utilization increased from the mid-200s in 2014 to nearly 900 admissions in 2023. Neurological (28.9%) and nephrological (24.4%) disorders were the leading subspecialties. Systemic lupus erythematosus (12.4%), septic shock (12.1%), and acute inflammatory demyelinating polyradiculoneuropathy (9.1%) were the most frequent disease-specific indications. Nearly three-quarters of procedures were guideline-supported (Category I: 28.6%, Category II: 31.7%), while Category III use was 28.1% in our cohort. In-hospital mortality was 51.6% overall, driven largely by septic shock and acute liver failure, whereas survival exceeded 70% in autoimmune neurologic diseases and transplant recipients. Complications included bleeding (25.5%), transfusion requirements (69.0%), and hypocalcemia (9.7%). The actual cost per admission ranged USD 4000–12000, while reimbursement covered USD 2000–7000. Conclusion: This first nationwide analysis of TPE in Thailand highlights increasing utilization, high-cost burden, and important differences from global practice. Strengthening registries, refining coding systems, and developing region-specific guidelines will be critical to optimize outcomes and sustainability.
dc.identifier.citationTherapeutic Apheresis and Dialysis (2026)
dc.identifier.doi10.1002/1744-9987.70148
dc.identifier.eissn17449987
dc.identifier.issn17449979
dc.identifier.scopus2-s2.0-105036366168
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/116424
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleTherapeutic Plasma Exchange in Thailand: A 10-Year Retrospective Analysis
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105036366168&origin=inward
oaire.citation.titleTherapeutic Apheresis and Dialysis
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationPhramongkutklao College of Medicine
oairecerif.author.affiliationBumrungrad International Hospital

Files

Collections